BR112022002094A2 - Composição imunogênica - Google Patents
Composição imunogênicaInfo
- Publication number
- BR112022002094A2 BR112022002094A2 BR112022002094A BR112022002094A BR112022002094A2 BR 112022002094 A2 BR112022002094 A2 BR 112022002094A2 BR 112022002094 A BR112022002094 A BR 112022002094A BR 112022002094 A BR112022002094 A BR 112022002094A BR 112022002094 A2 BR112022002094 A2 BR 112022002094A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- staphylococcus
- antigens
- prevention
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 3
- 241000191940 Staphylococcus Species 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Abstract
composição imunogênica.a presente invenção refere-se a uma composição imunogênica que compreende antígenos de staphylococcus, contendo antígenos de proteínas e conjugados de polissacarídeos capsulares. também são providas formulações com adjuvante. a invenção pode encontrar uso na prevenção e no tratamento de infecções causadas por staphylococcus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19191991.9A EP3777884A1 (en) | 2019-08-15 | 2019-08-15 | Immunogenic composition |
PCT/EP2020/072428 WO2021028402A1 (en) | 2019-08-15 | 2020-08-10 | Immunogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022002094A2 true BR112022002094A2 (pt) | 2022-04-19 |
Family
ID=67659013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022002094A BR112022002094A2 (pt) | 2019-08-15 | 2020-08-10 | Composição imunogênica |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220395566A1 (pt) |
EP (2) | EP3777884A1 (pt) |
JP (1) | JP2022544407A (pt) |
CN (1) | CN114585381A (pt) |
BR (1) | BR112022002094A2 (pt) |
CA (1) | CA3150545A1 (pt) |
MX (1) | MX2022001937A (pt) |
WO (1) | WO2021028402A1 (pt) |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
DE3071552D1 (en) | 1979-09-21 | 1986-05-22 | Hitachi Ltd | Semiconductor switch |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU614755B2 (en) | 1987-06-05 | 1991-09-12 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Autocrine motility factors in cancer diagnosis and management |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
NZ249704A (en) | 1992-02-11 | 1996-11-26 | Jackson H M Found Military Med | A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct |
EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
DK0689454T4 (da) | 1993-03-23 | 2005-05-30 | Smithkline Beecham Biolog | Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A |
ES2210262T3 (es) | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
WO1996029094A1 (en) | 1995-03-22 | 1996-09-26 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
US20030113350A1 (en) | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
WO2003074687A1 (en) | 2002-03-07 | 2003-09-12 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
ATE483027T1 (de) | 2005-05-11 | 2010-10-15 | Eth Zuerich | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
ES2387327T3 (es) | 2006-09-26 | 2012-09-20 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
US8895014B2 (en) | 2008-02-20 | 2014-11-25 | Glycovaxyn Ag | Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells |
SI3281947T1 (sl) | 2009-04-03 | 2020-07-31 | The University Of Chicago | Sestave in metode v zvezi z variantami proteina A (SPA) |
US8568735B2 (en) * | 2009-06-22 | 2013-10-29 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
CA2768485C (en) | 2009-07-16 | 2018-12-04 | Timothy Foster | Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a |
NZ597972A (en) | 2009-07-17 | 2013-06-28 | Ocean Harvest Technology Canada Inc | Natural and sustainable seaweed formula that replaces synthetic additives in fish feed containing ulva lactuca and ascophyllum nodosum |
NZ598654A (en) | 2009-09-02 | 2014-05-30 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
HUE037956T2 (hu) | 2010-05-06 | 2018-09-28 | Glaxosmithkline Biologicals Sa | Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák |
AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
JP2013538217A (ja) | 2010-09-01 | 2013-10-10 | ノバルティス アーゲー | 不溶性金属塩への免疫増強物質の吸着 |
SG190731A1 (en) | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
CN104902931A (zh) | 2012-09-10 | 2015-09-09 | 格林考瓦因有限公司 | 包含修饰的抗原的生物缀合物及其用途 |
BE1022875B1 (fr) * | 2014-03-26 | 2016-09-30 | Glaxosmithkline Biologicals S.A. | Compositions pour une immunisation contre staphylococcus aureus |
EA037818B1 (ru) | 2014-03-26 | 2021-05-25 | Глаксосмитклайн Байолоджикалс С.А. | Мутантные стафилококковые антигены |
WO2016107818A1 (en) | 2014-12-30 | 2016-07-07 | Glycovaxyn Ag | Compositions and methods for protein glycosylation |
GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
GB201721576D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
GB201802339D0 (en) * | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
-
2019
- 2019-08-15 EP EP19191991.9A patent/EP3777884A1/en not_active Ceased
-
2020
- 2020-08-10 EP EP20761759.8A patent/EP4013449A1/en active Pending
- 2020-08-10 CA CA3150545A patent/CA3150545A1/en active Pending
- 2020-08-10 MX MX2022001937A patent/MX2022001937A/es unknown
- 2020-08-10 BR BR112022002094A patent/BR112022002094A2/pt not_active Application Discontinuation
- 2020-08-10 WO PCT/EP2020/072428 patent/WO2021028402A1/en unknown
- 2020-08-10 JP JP2022509015A patent/JP2022544407A/ja active Pending
- 2020-08-10 CN CN202080072409.8A patent/CN114585381A/zh active Pending
- 2020-08-10 US US17/634,272 patent/US20220395566A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021028402A1 (en) | 2021-02-18 |
MX2022001937A (es) | 2022-03-11 |
EP4013449A1 (en) | 2022-06-22 |
EP3777884A1 (en) | 2021-02-17 |
CN114585381A (zh) | 2022-06-03 |
CA3150545A1 (en) | 2021-02-18 |
US20220395566A1 (en) | 2022-12-15 |
JP2022544407A (ja) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021015775A (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. | |
EP3616716A3 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
BR112018007525A2 (pt) | composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas | |
UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
RU2017123262A (ru) | Иммуногенные композиции для применения в пневмококковых вакцинах | |
CO6260103A2 (es) | Composiciones que comprenden antigenos neumococidos | |
EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
EA201691478A1 (ru) | Новый полисахарид и его применения | |
CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
AR059688A1 (es) | Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus | |
TW200633719A (en) | Glycoconjugate vaccines containing peptidoglycan | |
PE20190458A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
CR10555A (es) | Vacunas para malaria | |
BR112018075785A2 (pt) | formulação de vacina para o hiv | |
MA32388B1 (fr) | Immunomodulation par des inhibiteurs d'iap | |
CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
BR112017015288A2 (pt) | vacina contra febre aftosa | |
MA45283B1 (fr) | Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela | |
BRPI0820258B8 (pt) | composto, composições de vacina, e, uso de um composto | |
MX2022015734A (es) | Proteinas de exotoxina a modificadas. | |
BR112023001471A2 (pt) | Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |